German Atriva Therapeutics is launching a Phase II study of its investigational drug ATR-002 to treat Covid-19 in July this year.
ATR-002 has been developed specifically to treat RNA viral diseases, such as influenza and coronaviruses. It inhibits the Raf/MEK/ERK pathway, which is central to the replication of many RNA viruses. Atriva also believe ATR-002 has the potential to mitigate the cytokine storm, which has proven to be deadly in Covid-19 patients.
Atriva CEO and co-founder Dr Rainer Lichtenberger said: “With ATR-002, we developed a small molecule to specifically address the major need for an efficient antiviral therapy for severe respiratory infections caused by RNA viruses.
“ATR-002 could be a game changer in the current pandemic as we see high potential for a patient-friendly, oral medication that fundamentally impacts Covid-19 outcomes.
"To develop ATR-002 for Covid-19 is therefore a logical step in these times and possibly vital for national health systems, patients and families."